Personalized Pain Medicine

Personalized Pain Medicine

Below is an edited excerpt from a chapter titled, Pharmacogenetics and Personalized Medicine in Pain Management, that Inna Belfer, MD PhD and I published in Clinics in Laboratory Medicine, Volume 36, Issue 3, September 2016.  Personalized Pain Medicine Pharmacogenetic therapy in people with pain requires consideration of 2 different genetic substrates to determine the outcome…

Read More

Pain is a vital sign

Near the end of May, the New York Medical Society brought forward a resolution for the American Medical Association (AMA) House of Delegates to consider. The focus of Resolution 707 is the 2001 Joint Commission standard to assess pain as the fifth vital sign. The drafters of the resolution claim that this standard has led…

Read More

DEA Inflicts Harm on Chronic Pain Patients

In an effort to curb opioid drug abuse and addiction, the Drug Enforcement Administration (DEA) has issued new rules that limit the accessibility of hydrocodone, putting chronic pain sufferers who rely on the drug in an impossible situation. The DEA’s new restrictions come after the decision to relabel hydrocodone as a Schedule II drug, making…

Read More